KIF6

While Celera can potentially add to Quest's biomarker discovery capabilities and cardiovascular disease testing pipeline, private payors are still not reimbursing for a large share of Celera's products, which may impact how quickly Quest can see a return on its investment.

UCSF will use Celera's KIF6 genetic variant discoveries to develop a test for cardiovascular risk and statin benefit.

Medco wants to know if a gene variant test could predict patient adherence to statin treatment.

Milwaukee-based Aurora Health Care will use Celera's KIF6 test in its heart health programs.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.